CLYYF Projected Dividend Yield

Celyad Oncology SA ( OTCBB : CLYYF )

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. Co.'s primary product candidates include: CYAD-101, which is an investigational, non-gene edited, allogeneic CAR T candidate engineered to co-express a CAR based on natural killer group 2D ligands, a receptor expressed on natural killer cells that binds to eight stress-induced ligands and T cell receptor inhibitory molecule; and CYAD-211, which is an investigational, short hairpin RNA-based allogeneic CAR T candidate for the treatment of relapsed / refractory multiple myeloma.

20 YEAR PERFORMANCE RESULTS